Unlock more results with a Fundz subscription — Get started today!
Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.
Amberstone Biosciences Secures $12 Million Series A Financing To Advance Immuno-Oncology Pipeline Of Tumor Microenvironment Activated Therapeutics
Amberstone Biosciences Secures $12 Million Series A Financing To Advance Immuno-Oncology Pipeline Of Tumor Microenvironment Activated Therapeutics
01/03/22, 11:00 AM
Location
laguna hillsMoney raised
$12 million
Round Type
series a
Amberstone Biosciences (www.amberstonebio.com), an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders.
Company Info
Never Miss an Opportunity: Your #1 Sales Intelligence Tool
Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.